NCT06720090

Brief Summary

The goal of this clinical trial is to test whether light therapy is effective for reducing symptoms in young adults with OCD and late bedtimes (1am or later). The main question\[s\] it aims to answer are: Does light therapy reduce OCD symptoms? Does light therapy advance the circadian clock? If there is a comparison group: Researchers will compare a higher dose of light therapy to a lower dose to see if dose amount affects symptom reduction. Participants will asked to:

  1. 1.Wear light therapy glasses for 1 hour each morning and complete a daily light therapy log for 5 weeks
  2. 2.Track their sleep every day with a wearable monitor and an electronic sleep diary for 5 weeks
  3. 3.Complete a 1-time assessment of sensitivity to light exposure
  4. 4.Complete self-report measures of OCD 4 times/day at baseline (2 weeks), mid-treatment (1 week), and end of treatment (1 week)

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for early_phase_1

Timeline
34mo left

Started Dec 2024

Longer than P75 for early_phase_1

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress33%
Dec 2024Mar 2029

First Submitted

Initial submission to the registry

November 21, 2024

Completed
15 days until next milestone

First Posted

Study publicly available on registry

December 6, 2024

Completed
10 days until next milestone

Study Start

First participant enrolled

December 16, 2024

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2029

Last Updated

July 15, 2025

Status Verified

March 1, 2025

Enrollment Period

4.2 years

First QC Date

November 21, 2024

Last Update Submit

July 14, 2025

Conditions

OCD

Keywords

ocdsleeplight therapycircadianbehavioral treatment

Outcome Measures

Primary Outcomes (2)

  • Yale Brown Obsessive-Compulsive Scale (YBOCS)

    A retrospective clinical interview of OCD symptom severity. Score range from 0 to 40 and higher scores indicate more severe OCD symptoms.

    Administered at baseline, in treatment week 3, and post-treatment (3 administrations over 7 weeks)

  • Daily Perseverative Thinking Questionnaire

    Self-report measure of momentary transdiagnostic repetitive negative thinking. Score range from 6 to 42 and higher scores indicate more severe repetitive negative thinking.

    Administered 4 times/day for 2 weeks at baseline, 4 times/day for 1 week in treatment week 3, and 4 times/day for 1 week in treatment week 5

Secondary Outcomes (1)

  • Circadian melatonin phase

    At baseline and post-treatment (after 5 weeks of treament)

Study Arms (2)

Higher dose

EXPERIMENTAL

Participants will be given wearable light therapy devices that emit a higher light intensity.

Behavioral: Light therapy

Lower dose

SHAM COMPARATOR

Participants will be given wearable light therapy devices that emit a lower light intensity.

Behavioral: Light therapy

Interventions

Light therapyBEHAVIORAL

5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.

Higher doseLower dose

Eligibility Criteria

Age17 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Primary DSM-5 OCD diagnosis
  • Bedtime 0100 or later
  • Age 18-35
  • English speaking

You may not qualify if:

  • Subjects must not be currently participating in another research study that would influence their participation in our study.
  • Diagnostic status
  • Treatment status
  • Night shift work or travel more than 1 time zone outside of Central Standard Time (CST) in the past month
  • Pregnancy status
  • Medication status
  • Regular nicotine or marijuana use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington University

St Louis, Missouri, 63130, United States

RECRUITING

MeSH Terms

Conditions

Compulsive Personality Disorder

Interventions

Phototherapy

Condition Hierarchy (Ancestors)

Personality DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Rebecca Cox, PhD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rebecca Cox, BA

CONTACT

314-935-8111scraplab@wustl.edu

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

November 21, 2024

First Posted

December 6, 2024

Study Start

December 16, 2024

Primary Completion (Estimated)

March 1, 2029

Study Completion (Estimated)

March 1, 2029

Last Updated

July 15, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

Locations

US(1)